Anavex Life Sciences Corp (AVXL)

[crescentmotor]

Blarc may quailfy for Breakthrough Therapy, meeting the requirement of “A significantly improved safety profile compared to available therapy, with evidence of similar efficacy.”

Agree with you with regard to Blarcamesine. Using the same logic and based on the trial data, I also think SAVA's Simufilam may, a little further down the road, also be awarded BTD designation, especially since Simufilam is having some positive effective on even moderate stage AD patient in addition to mild stage.